Telix Pharmaceuticals Limited (TLX)
Nasdaq · Healthcare · Biotechnology
$10.88+3.13%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $3.7B
- P/E (trailing)
- 108.8
- 52-week range
- $6.28 – $13.11
- 52-week change
- +6.03%
- EPS (trailing)
- $0.10
- Analyst rating
- 1.0 Strong buy
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer.
Headquarters: North Melbourne, Australia · 1,120 employees · telixpharma.com